VIRP.PA
Virbac SA

Healthcare · Drug Manufacturers - General · valued as of 2026-11-03 · statements 2025-12-31

Average Intrinsic Value

2.10B USD

Market Cap

3.26B USD

Margin of Safety

-55.0%

Intrinsic / Market Ratio

0.65×

Projections, not exact values. Intrinsic Values are projected from each company's past reports. They show which stocks look cheap compared with the others, not exactly what a stock is worth.

How Each Value Is Built

The screener's three formulas on the reported figures. Each card reads the same way: the value as a sum of numbered terms, each term's calculation opened under it, from the reported figures to the value. The list ranks companies by their plain average over the market cap.

EPV + Growth

2.12B USD

what the normal year's earnings are worth for ever, plus growth that pays

Profit

2.17B USD

15 years of cash the shareholders can take out, and the equity left at year 15

FCFF

2.02B USD

15 years of cash for shareholders and lenders, less what is owed

Intrinsic Value

2.10B USD

the plain average of the three, uncapped, as the screener averages them

Intrinsic Value

2.10B USD

from the sum above

Market Cap

3.26B USD

the price on the date above times the shares

Intrinsic Value ÷ Market Cap

0.65×

the ratio the screener ranks by; Margin of Safety -55.0% (1 − Market Cap ÷ Intrinsic Value)

Each card below builds one of the three values from the reported years.

Earnings power value plus growth: 2.12B USD
What the normal year's operating profit after tax is worth if it lasts for ever, plus what the new investment adds beyond its cost, less the net debt that comes before the shareholders (or plus the net cash).
①EPV (earnings power value)2.15B USD
−②Net Debt Today195.59M USD
+③Growth Value163.58M USD
=Value2.12B USD

EPV of the Operations (NOPAT over WACC)

2.15B USD

Net debt today

-195.59M USD

Growth Value

+163.58M USD

Value

2.12B USD

①EPV (earnings power value)

2.15B USD

②Net Debt Today

195.59M USD

③Growth Value

163.58M USD

Market value

Market Cap3.26B USD

The price on the date above times the shares.

Value vs market

Margin of Safety-53.8%

1 minus the market cap as a share of the value.

Profit value: today's value of the shareholders' equity, from the cash it can pay them (FCFE): 2.17B USD
Fifteen years of free cash flow to equity (FCFE), each brought to today at the cost of equity, plus the equity at year 15 brought to today.
①Present Value of the 15 Years of FCFE1.22B USD
+②Equity at Year 15, Today947.13M USD
=Value2.17B USD
FCFE: the net income left for the shareholders once the business keeps what next year's growth needsEquity reinvestment: the part of the year's net income kept in the business to grow the next year; below zero, capital the business releases to the shareholdersPresent value of the FCFEColoured bars show the FCFE, grey bars the equity reinvestment. With a positive equity reinvestment the two stacked are the year's normalized income; with a negative one the grey is below zero, capital the business releases, and the normalized income is the FCFE plus that negative amount. Shaded, years 6 to 10: the growth falling to its long-run rate and the ROE on new investment falling to the cost of equity. Axes linear.

①Present Value of the 15 Years of FCFE

1.22B USD

②Equity at Year 15, Today

947.13M USD

Market value

Market Cap3.26B USD

The price on the date above times the shares.

Value vs market

Margin of Safety-50.5%

1 minus the market cap as a share of the value.

FCFF value: today's value of the shareholders' equity, from the cash the firm can pay its shareholders and lenders (FCFF): 2.02B USD
Fifteen years of free cash flow to the firm (FCFF), each brought to today at the WACC, plus the invested capital at year 15 brought to today, less the net debt today (or plus the net cash).
①Present Value of the 15 Years of FCFF1.49B USD
+②Invested Capital at Year 15, Today727.52M USD
−③Net Debt Today195.59M USD
=Value2.02B USD
FCFF: the NOPAT left for the shareholders and the lenders once the business reinvests what next year's growth needsReinvestment: the part of the year's NOPAT put back into the business to grow the next year; below zero, capital the business releasesPresent value of the FCFFColoured bars show the FCFF, grey bars the reinvestment. With a positive reinvestment the two stacked are the year's NOPAT; with a negative one the grey is below zero, capital the business releases, and the NOPAT is the FCFF plus that negative amount. Shaded, years 6 to 10: the growth falling to its long-run rate and the ROIC on new investment falling to the WACC. Axes linear.

①Present Value of the 15 Years of FCFF

1.49B USD

②Invested Capital at Year 15, Today

727.52M USD

③Net Debt Today

195.59M USD

Market value

Market Cap3.26B USD

The price on the date above times the shares.

Value vs market

Margin of Safety-61.2%

1 minus the market cap as a share of the value.

The Rates and the Capital the Values Read

The WACC and the cost of equity each value is discounted at, the book value and the net debt each starts from, and the seven quality metrics, from the same run.

WACC: 8.58%
Cost of Equity =Risk-Free Rate 4.50%+Beta 0.79×Market Risk Premium 6.00%= 9.26%

The yearly return the shareholders require for the risk they carry; it is the rate that brings their future cash to today.

Tax Rate for WACC =Tax Provision 79.07M USDPretax Income 255.76M USD= 30.92%

The tax the interest saves.

Interest Expense =EBIT 266.15M USD−Pretax Income 255.76M USD= 10.39M USD

The interest the company paid: EBIT is the profit before tax plus the interest.

Cost of Debt =Interest Expense 10.39M USDTotal Debt 339.64M USD×(1 − Tax Rate for WACC 30.92%)= 2.11%

What the lenders are paid a year after the tax the interest saves.

Debt Weight =Total Debt 339.64M USDMarket Cap + Total Debt 3.26B USD + 339.64M USD= 9.43%

The part of the capital the lenders put in, at market value.

WACC =Equity Weight 90.57%×Cost of Equity 9.26%+Debt Weight 9.43%×Cost of Debt 2.11%= 8.58%

Weighted average cost of capital: the yearly return the shareholders and the lenders together require, weighted by what each puts in; the rate that brings the firm's future cash to today.

Book value and net debt today
Both from the balance sheet of the newest quarter, 2025-12-31.

Total Assets 2.25B USD − Total Liabilities 928.01M USD = Book Value Today 1.32B USD

Total Debt 339.64M USD − Cash and Short-Term Investments 144.05M USD = Net Debt Today 195.59M USD

The book value is what Profit starts from and what stands when a projection is not made; the book value plus the net debt is what FCFF starts from; the net debt comes off Greenwald's and FCFF's values before the shareholders.

Quality metrics
Read beside the value, never a condition for it: every company is valued, and a filter in the list is the reader's choice.
MetricFrom
Share dilutionShares Today ÷ Shares Two Years Back − 10.1%at most 5%passes8,377,824 / 8,369,719
Accrual quality(Operating Cash Flow − Net Income) ÷ Total Assets2.5%at least -10.0%passes(233.99M USD − 177.43M USD) ÷ 2.25B USD
Price to bookMarket Cap ÷ Book Value Today2.47×at most 3×passes3.26B USD ÷ 1.32B USD
Operating marginOperating Income ÷ Revenue15.7%above 10.0%passes270.63M USD ÷ 1.72B USD
Revenue growthRevenue ÷ Revenue a Year Before − 118.3%above 10.0%passes1.72B USD / 1.46B USD
Net cash(Cash − Total Debt) ÷ Market Cap-6.0%above -30%passes(144.05M USD − 339.64M USD) ÷ 3.26B USD
Operating efficiencyOperating Income ÷ Gross Profit23.6%above 25.0%does not pass270.63M USD ÷ 1.15B USD

Market Data

The provider's ratios and the analysts' consensus beside the argument; none of them enters a value.

Share price

347.35 EUR

Enterprise value

3.13B EUR

the provider's own figure

EV / EBITDA

10.70×

Price / book

2.39×

the provider's book

Price / earnings

18.68×

Return on equity

13.6%

the provider's figure, not this page's

Profit margin

10.4%

Revenue growth

4.0%

Analyst target, mean

411.16 EUR

Analysts

8

opinions in the consensus

Financial Statements

The annual lines the screener holds, year by year, in USD at each period's rate; the figures this valuation read are in its calculation above.

USD2022202320242025
Income statement

Revenue

1.30B1.38B1.46B1.72B

Gross profit

843.01M896.97M976.66M1.15B

Operating income

195.79M205.75M237.82M270.63M

EBITDA

operating income before depreciation and amortisation

244.59M255.55M287.77M337.40M

Pretax income

188.29M192.95M216.45M255.76M

Net income

130.13M134.39M151.34M177.43M

Normalized income

net income without one-off items, as the data provider prints it; Profit's line when printed

135.71M131.18M161.17M162.41M

R&D

————
Balance sheet, year end

Total assets

1.42B1.61B1.93B2.25B

Total liabilities

527.52M604.72M838.66M928.01M

Shareholders' equity

the equity the parent's shareholders own, as printed, without minority interest; the book value the values read is total assets less total liabilities, in Book Value and Net Debt above

896.01M997.47M1.09B1.32B

Total debt

96.46M133.07M319.80M339.64M

Cash and equivalents

189.29M194.89M155.86M144.05M

Net PP&E

fixed assets after depreciation

293.72M333.44M452.49M542.97M

Working capital

current assets less current liabilities

355.30M412.63M395.37M324.06M
Cash flow

Operating cash flow

105.63M131.45M212.73M233.99M

Capital expenditure

paid out, so below zero

-57.17M-66.37M-83.79M-120.11M

Depreciation and amortisation

52.36M52.76M59.74M71.25M

Free cash flow

operating cash flow plus capital expenditure

48.46M65.08M128.94M113.89M